Moldova latest patents query
The latest invention patents collect the data information of Moldova invention patents from 2000 to 2024, typesetting according to the date of patent publication, including patent number, application date, invention Bibliographic data, abstracts, and specification data of people are convenient for scientific researchers to quickly browse and search for patents.
Spirocyclic dihydropyranopyrimidine KRas inhibitors
PendingMDE20260493A1
Owner:TREELINE BIOSCIENCES INC
Process for producing (3S,6R)-6-(cyanomethyl)- tetrahydro-2H-pyran-3-amine
PendingMDE20260477A1
Owner:BIOHAVEN THERAPEUTICS LTD
Extended-release formulations of Kv7.2 / 7.3 potassium channel activators
PendingMDE20260476A1
Owner:BIOHAVEN THERAPEUTICS LTD
Modified sequence of adenovirus E2a gene for producing vectors based on adeno-associated viruses (AAV) (variants)
PendingMDE20260479A1
Owner:JOINT CO BIOCAD
Oral pharmaceutical dosage form providing immediate release of vidofludimus
PendingMDE20260484A1
Owner:IMMUNIC AG
Fluoroalkoxyalkylene-dihydroimidazo[5,1-d]tetrazinone compounds and related compounds and their use in treating medical conditions
PendingMDE20260462A1
Owner:MODIFI BIOSCIENCES INC
ENPP3 and CD3 binding agents and methods of use thereof
PendingMDE20260473A1
Owner:JANSSEN BIOTECH INC
Bicyclic heteroaryl-containing piperidine inhibitors of SLC6A19 function
PendingMDE20260481A1
Owner:JNANA THERAPEUTICS INC
Naphthyl-containing piperidine inhibitors of SLC6A19 function
PendingMDE20260496A1
Owner:JNANA THERAPEUTICS INC
A water-soluble afoxolaner complex, a method for producing thereof and veterinary antiparasitic drugs comprising the same
PendingMDE20260467A1
Owner:SYNYTSYA YURIY YURIYOVYCH
Guselkumab for use in the treatment of Crohn's disease with a dosage regimen
PendingMDE20260482A1
Owner:JANSSEN BIOTECH INC
Aminoadipate-semialdehyde synthase (AASS) iRNA compositions and methods of use thereof
PendingMDE20260463A1
Owner:ALNYLAM PHARMACEUTICALS INC
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (TGFBR2)
PendingMDE20260494A1
Owner:INTELLIA THERAPEUTICS INC
Methods of improving transplant survival using IL-2 receptor gamma chain antibodies
PendingMDE20260134A1
Owner:REGENERON PHARMACEUTICALS INC
Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
PendingMDE20260658A1
Owner:INTRABIO LTD
Sparsentan for use in a method of treating IgA-mediated diseases
PendingMDE20260287A1
Owner:TRAVERE THERAPEUTICS INC
Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders secondary to retinal vein occlusion
PendingMDE20260632A1
Owner:REGENERON PHARMACEUTICALS INC +1
G protein-coupled receptor (GPCR) modulation by imipridones
PendingMDE20260174A1
Owner:ONCOCEUTICS INC
Heating system for the generation of domestic hot water and heat transfer fluid
PendingMDE20260363A1
Owner:SONIC TECHNOLOGY SRL
First line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer
PendingMDE20260649A1
Owner:JANSSEN BIOTECH INC
New method of producing an aqueous mesoparticle composition comprising a lipophilic compound
PendingMDE20260357A1
Owner:BIOGNTX R&D BV
A fertilizer comprising biomass and a method of its manufacturing
PendingMDE20260419A1
Owner:EVERGREEN SOLUTIONS SP ZOO PL
The VMAT2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
PendingMDE20260630A1
Owner:NEUROCRINE BIOSCIENCES INC
Drug delivery system for the treatment of female sexual interest and arousal disorder
PendingMDE20260553A1
Owner:ARLETTA PHARMA SOLUTIONS HOLDING BV
A new vamorolone preparation exhibiting improved solubility
PendingMDE20250941A1
Owner:SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH
Benzimidazole and benzimidazolone based PROTAC compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2)
PendingMDE20260019A1
Owner:ARVINAS OPERATIONS INC
Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors
PendingMDE20260424A1
Owner:HIRUNDO BIOSCIENCES
Display panel, particularly for interchangeable traffic signs
PendingMDE20260093A1
Owner:SWARCO FUTURIT VERKEHRSSIGNALSYSTEME GES MBH
Fused ring KRAS inhibitors for treating disease
PendingMDE20260238A1
Owner:BLOSSOMHILL THERAPEUTICS INC
Methods for treating prostate cancer with bispecific antibodies binding STEAP1xCD3
PendingMDE20260505A1
Owner:AMGEN RESEARCH (MUNICH) GMBH +1
Conjugates, compositions and methods for treating influenza
PendingMDE20260675A1
Owner:PURDUE RES FOUND +1
Determining effect of a drug based on brain activity and a trained machine learning model
PendingMDE20260576A1
Owner:PRAXIS PRECISION MEDICINES INC
A process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion
PendingMDE20260329A1
Owner:PICO IP LLC
Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
PendingMDE20260706A1
Owner:REGENERON PHARMACEUTICALS INC +1
Method for diagnosing amyloid diseases
PendingMDE20260558A1
Owner:UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Antibody-drug conjugates for delivering cytotoxic agents
PendingMDE20260215A1
Owner:BIOHAVEN THERAPEUTICS LTD
Low pH pharmaceutical composition comprising T cell engaging antibody constructs
PendingMDE20260594A1
Owner:AMGEN RESEARCH (MUNICH) GMBH +1
Blood plasma fractions as a treatment for aging-associated cognitive disorders
PendingMDE20260422A1
Owner:ALKAHEST INC
Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof
PendingMDE20260282A1
Owner:CILOA +1
Connecting end, fluid connector, and liquid cooling device
PendingMDE20260517A1
Owner:SHENZHEN ENVICOOL INTELLIGENT CONNECTION TECHNOLOGY CO LTD CN
Electronic module for a metered dose inhaler and metered dose inhaler assembly comprising the electronic module
PendingMDE20260427A1
Owner:CHIESI FARMACEUTICI SPA
Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
PendingMDE20260407A1
Owner:TRAVERE THERAPEUTICS INC
Mitigation of positioning measurement impact on RLF procedure
PendingMDE20250937A1
Owner:NOKIA TECHNOLOGIES OY
PPARG inverse agonists and immunotherapies for treating cancer
PendingMDE20260689A1
Owner:FLARE THERAPEUTICS INC
Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
PendingMDE20260226A1
Owner:REGENERON PHARMACEUTICALS INC
Mutated adenoviruses with improved replication and their use for treating cancer
PendingMDE20260394A1
Owner:THEOLYTICS LTD
Oral solid pharmaceutical formulation comprising methadone / levomethadone and optionally naloxone
PendingMDE20260308A1
Owner:L MOLTENI & C DEI FRAT ALITTI SOC DI ESERCIZIO SPA
System and method for calculating the energy footprint of a hotel unit depending on the choices of the guest
PendingMDE20260525A1
Owner:ANGELIDIS THOMAS +2
CRISPR nuclease polypeptides and gene editing systems comprising such
PendingMDE20260131A1
Owner:ARBOR BIOTECHNOLOGIES INC
Stealth lipid nanoparticle compositions for cell targeting
PendingMDE20260699A1
Owner:GENERATION BIO CO
RNA-guided nucleases and active fragments and variants thereof and methods of use
PendingMDE20260671A1
Owner:LIFEEDIT THERAPEUTICS INC
6-(6-(((1R,2R,3S,5S)-2-Fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3- yl)-2-methylbenzo[d]oxazol-5-ol as a splicing modulator for the treatment of neurological diseases
PendingMDE20260361A1
Owner:SKYHAWK THERAPEUTICS INC
Process for preparing (2S,4S,4'S,6S)-2-methyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran]-4'-ol
PendingMDE20260566A1
Owner:VERTEX PHARMACEUTICALS INC
Fluid connector and connector lock system thereof
PendingMDE20260608A1
Owner:SHENZHEN ENVICOOL INTELLIGENT CONNECTION TECHNOLOGY CO LTD CN
Isolated bispecific antibody that specifically binds to CD3 and tumor antigen, and use thereof
PendingMDE20260079A1
Owner:JOINT CO BIOCAD
Methods and compositions for inhibiting progression of intramuscular fibrosis
PendingMDE20260053A1
Owner:DYNE THERAPEUTICS INC
Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof
PendingMDE20260384A1
Owner:SHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD
Crystalline forms of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile
PendingMDE20260645A1
Owner:INCYTE CORP
Nuclear localization polypeptides and conjugates and uses thereof
PendingMDE20260127A1
Owner:ADCYTHERIX SAS
New uses of aqueous solutions with high hydrogen concentration
PendingMDE20260625A1
Owner:BLUE HYDROGEN SCI SRL
Methods for treatment of non-small cell lung cancer (NSCLC)
PendingMDE20260264A1
Owner:JANSSEN BIOTECH INC
Polypeptide and antibody containing same acting as light-chain
PendingMDE20260014A1
Owner:KYINNO BIOTECHNOLOGY (BEIJING) CO LTD
Method for determining the presence of native natural intelligence in epigenau / 11 product for restoring homeostasis in tissues infiltrated by cancer cells
PendingMDE20260183A1
Owner:BIOS-THERAPY PHYSIOLOGICAL SYSTEMS FOR HEALTH SPA IT
Systems and methods for operating an overhead electrical line
PendingMDE20260148A1
Owner:CTC GLOBAL CORP
4-Pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives as mutant PAH protein stabilizers for the treatment of phenylketonuria
PendingMDE20260531A1
Owner:AGIOS PHARMACEUTICALS INC
Activin A receptor type 1C (ACVR1C) iRNA compositions and methods of use thereof
PendingMDE20260588A1
Owner:ALNYLAM PHARMACEUTICALS INC
Treatment of hematological malignancies with antibodies inhibiting galectin-9
PendingMDE20260677A1
Owner:PURETECH LYT INC
Pharmaceutical compositions comprising a bispecific BCMA / CD3 antibody at high concentration
PendingMDE20260230A1
Owner:JANSSEN BIOTECH INC
Pharmaceutical compositions including tolinapant and packaging
PendingMDE20260449A1
Owner:TAIHO PHARMA CO LTD
System of construction elements for jointless erection of building walls
PendingMDE20260015A1
Owner:WARGACKI PIOTR
Enzymatic glycosylation of trichothecene mycotoxins
PendingMDE20260516A1
Owner:HIS MAJESTY THE KING IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF AGRICULTURE & AGRI-FOOD CA
Method of electronic association between elements and payment systems
PendingMDE20260062A1
Owner:CORNER BANCA SA
Antisense oligomers for treatment of chronic kidney disease
PendingMDE20260192A1
Owner:SAREPTA THERAPEUTICS INC
Stabilized formulations containing anti-BCMA x anti-CD3 bispecific antibodies
PendingMDE20260378A1
Owner:REGENERON PHARMACEUTICALS INC
Ensifentrine for use in treating chronic obstructive pulmonary disease (COPD)
PendingMDE20260555A1
Owner:VERONA PHARMA
Process for the production of high-purity alumina (HPA)
PendingMDE20260030A1
Owner:ECOTEC TIONE IMPIANTI
Dihydropyrimidine-2,4(1H, 3H)-dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
PendingMDE20260320A1
Owner:HANGZHOU GLUBIO PHARM CO LTD
Crystalline salts of a T-type calcium channel modulator and methods of use thereof
PendingMDE20260057A1
Owner:PRAXIS PRECISION MEDICINES INC
Methods for producing triterpenoid derivatives
PendingMDE20260447A1
Owner:REATA PHARMACEUTICALS HOLDINGS LLC
Respiratory syncytial virus F proteins and nanostructures and uses thereof
PendingMDE20260578A1
Owner:ICOSAVAX INC
A multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride free of titanium dioxide
PendingMDE20260262A1
Owner:ITALFARMACO SPA
High strength single unit dose formulations and methods of use thereof
PendingMDE20260056A1
Owner:PRAXIS PRECISION MEDICINES INC
Method of stabilising nonwoven fibres and reusable moisture absorbing articles
PendingMDE20260144A1
Owner:RSD HLDG LTD
A cabinet or frame-mountable photovoltaic array for sub-optimal solar power conversion and methods and apparatus for maximising collection efficiency
PendingMDE20260028A1
Owner:BRIGGS MAURICE
Methods for predicting response to pharmacological agents in patients with obesity
PendingMDE20260091A1
Owner:PHENOMIX SCIENCES INC +1
Antibody variable domains and antibodies having decreased immunogenicity
PendingMDE20260245A1
Owner:NUMAB THERAPEUTICS AG
Gene editing method for inhibiting aberrant splicing in stathmin 2 (STMN2) transcript
PendingMDE20260012A1
Owner:ARBOR BIOTECHNOLOGIES INC
Systems and methods for regulating the use of carbon neutral fuels in regulated vehicles
PendingMDE20260458A1
Owner:INFINIUM TECHNOLOGY LLC
Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine
PendingMDE20260221A1
Owner:TAIHO PHARMA CO LTD
5-Oxo-4,5-dihydroimidazo[1,5-a]quinazoline compounds as PI3K[alpha] inhibitors
PendingMDE20260664A1
Owner:PIKAVATION THERAPEUTICS INC
Methods of treating cancer with bispecific anti-CD22 x anti-CD28 molecules
PendingMDE20260086A1
Owner:REGENERON PHARMACEUTICALS INC
Compounds and methods for reducing APP expression
PendingMDE20260017A1
Owner:IONIS PHARMACEUTICALS INC
Advertising frame mounted with an advertising frame filling
PendingMDE20260059A1
Owner:FLAGOWA KRAINA SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA PL
Electrified steam-methane-reforming reactor and methods of use
PendingMDE20260237A1
Owner:INFINIUM TECHNOLOGY LLC
Composition for producing concrete, in particular lightweight porous concrete and high-performance concrete, mortar, floating screed and filler, and method for the production and use thereof
PendingMDE20260563A1
Owner:HEID MASCHF
A natural matrix mixture for the treatment of bone fragility
PendingMDE20260170A1
Owner:BIOS-THERAPY PHYSIOLOGICAL SYSTEMS FOR HEALTH SPA IT